48,229 Shares in Alto Neuroscience, Inc. (NYSE:ANRO) Purchased by Graham Capital Management L.P.

Graham Capital Management L.P. bought a new stake in shares of Alto Neuroscience, Inc. (NYSE:ANRO) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 48,229 shares of the company’s stock, valued at approximately $204,000. Graham Capital Management L.P. owned 0.18% of Alto Neuroscience as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Wells Fargo & Company MN raised its stake in shares of Alto Neuroscience by 40.0% during the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock valued at $46,000 after purchasing an additional 3,139 shares in the last quarter. Deutsche Bank AG increased its stake in Alto Neuroscience by 31.3% during the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after buying an additional 3,629 shares during the period. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Alto Neuroscience during the 4th quarter worth about $74,000. Jane Street Group LLC lifted its stake in shares of Alto Neuroscience by 72.0% in the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock worth $79,000 after acquiring an additional 7,783 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Alto Neuroscience by 24.4% in the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock valued at $108,000 after acquiring an additional 5,008 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. HC Wainwright initiated coverage on Alto Neuroscience in a research report on Monday, April 7th. They issued a “buy” rating and a $10.00 target price for the company. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a report on Friday, March 21st. Finally, Wedbush reaffirmed a “neutral” rating and set a $4.00 target price on shares of Alto Neuroscience in a research note on Thursday. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Alto Neuroscience has an average rating of “Moderate Buy” and a consensus price target of $15.40.

Alto Neuroscience Stock Performance

Shares of NYSE ANRO opened at $2.55 on Monday. The stock’s fifty day simple moving average is $2.37 and its 200 day simple moving average is $3.43. The stock has a market capitalization of $69.06 million, a price-to-earnings ratio of -1.09 and a beta of 1.87. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience, Inc. has a 52-week low of $1.60 and a 52-week high of $17.55.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.06. As a group, sell-side analysts forecast that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.